Member Log-in

I forgot my password

Not a Member? Register

Papillomavirus Rapid Interface for Modelling and Economics (PRIME) Tool

The spreadsheet-based PRIME tool is intended for in-country analysts (not necessarily economists) who are advising national governments on HPV vaccine introduction.

PRIME is designed to give users an idea of:

    • The magnitude of the burden of cervical cancer
    • The impact of introducing HPV vaccination for girls prior to sexual debut
    • Healthcare costs incurred as a result of cervical cancer treatment
    • Costs associated with vaccination
    • Long-term savings which may result from a vaccination program

The tool is intended for use by non-modeller users such as country program managers and planners and decision makers in low- and middle income countries. It was created by scientists at the London School of Hygiene and Tropical Medicine in London and Université Laval in Quebec in conjunction with the World Health Organization in Geneva. It has been appraised by WHO’s expert committee on modelling, IVIR-AC. It gives reliable, validated estimates for impact and cost-effectiveness of HPV vaccination of adolescent girls prior to sexual debut.

You May Also Like

Assessing the Incremental Costs and Savings of Introducing Electronic Immunization Registries and Stock Management Systems: Evidence from the Better Immunization Data Initiative in Tanzania and Zambia

Introduction: poor data quality and use have been identified as key challenges that negatively impact immunization programs in low- and middle-income countries (LMICs). In addition, many LMICs have a shortage of health personnel, and staff available have demanding workloads across several health programs. In order to address these challenges, the Better Immunization Data (BID) Initiative … Continued

Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30

ABSTRACT Estimating the value of global investment in immunization programs is critical to helping decision makers plan and mobilize immunization programs and allocate resources required to realize their full benefits. We estimated economic benefits using cost-of-illness and value-of-a-statistical-life approaches and combined this estimation with immunization program costs to derive the return on investment from immunization … Continued

Routine Childhood Immunization During the COVID-19 Pandemic in Africa: A Benefit–risk Analysis of Health Benefits Versus Excess Risk of SARS-CoV-2 Infection

Background National immunization programs globally are at risk of suspension due to the severe health system constraints and physical distancing measures in place to mitigate the ongoing COVID-19 pandemic. We aimed to compare the health benefits of sustaining routine childhood immunization in Africa with the risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) … Continued

Choose a Language